Summary
The pharmacokinetics of the dipyrone metabolites 4-methylaminoantipyrine (MAA), 4-aminoantipyrine (AA), 4-formylaminoantipyrine (FAA) and 4-acetylaminoantipyrine (AAA) were evaluated following the administration of a single oral 1.0 g dose of dipyrone to 23 healthy volunteers. Twelve were slow and 11 were rapid acetylators as previously determined by dapsone phenotyping. For MAA and FAA the mean peak plasma concentrations were 10.5±2.8 µg/ml and 2.1±0.8 µg/ml and the half-lives were 3.3±1.0 and 10.1±1.8 h, respectively. No significant difference was found between rapid and slow acetylators in MAA and FAA kinetics. For AA, the mean peak plasma concentrations were 2.7±0.6 and 1.6±0.7 µg/ml (p<0.01), the peak times 6.7±2.1 and 3.1±1.1 h (p<0.01) and the half-lives were 5.5±1.0 and 3.8±1.2 h in slow and rapid acetylators, respectively. For AAA, the mean peak plasma concentrations were 1.6±0.4 and 4.4±1.1 µg/ml (p<0.01) and the peak time 16.1±5.1 and 10.0±2.6 h (p<0.01) in slow and rapid acetylators, respectively. There was no difference in the elimination half-life between the two groups (10.6±2.2 h). Thus, it has been demonstrated that the AAA/AA ratio is an indicator of the acetylation phenotype, as it is closely correlated with that determined by dapsone (r=0.895, p<0.0005).
Similar content being viewed by others
References
Christ O, Kellner HM, Ross G, Rupp W, Schwarz A (1973) Biopharmazeutische und pharmakokinetische Untersuchungen nach Gabe von Metamizol 14C an Ratte, Hund und Mensch. Arzneimittelforsch 23: 1760–1767
Weiss R, Brauer J, Goertz U, Petry R (1974) Vergleichende Untersuchungen zur Frage der Absorption und Metabolisierung des Pyrazolonderivates Metamizol nach oraler und intramuskularer Gabe beim Menschen. Arzneimittelforsch 24: 345–348
Volz M, Kellner HM (1980) Kinetics and metabolism of pyrazolones (propyhenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 299S–308S
Iguchi S, Goromaru T, Noda A (1975) A new metabolite of aminopyrine (aminophenazone) in man, 4-formylaminoantipyrine. Chem Pharm Bull 23: 932–934
Noda A, Goromaru T, Tsubone N, Matsuyama K, Iguchi S (1976) In-vivo formation of 4-formyl-aminoantypyrine as a new metabolite of aminopyrine. Chem Pharm Bull 24: 1502–1506
Goromaru T, Matsuyama K, Noda A, Iguchi S (1978) The measurement of plasma concentration of aminopyrine and its metabolites in man. Chem Pharm Bull 26: 33–37
Zylber-Katz E, Granit L, Drayer DE, Levy M (1984) Simultaneous determination of dipyrone metabolites in plasma by high-performance liquid chromatography. J Chromatogr 305: 477–484
Reidenberg MM, Martin JH (1974) Acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Dispos 2: 71–73
Eldor A, Polliack G, Vlodavsky I, Levy M (1983) Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. Thromb Haemost 49: 132–137
Weber WW (1973) Acetylation of drugs. In: Fishman WH (ed) Metabolic conjugation and metabolic hydrolysis, vol 3. Academic Press, New York, pp 249–296
Levy M (1980) Epidemiological evaluation of rare side effects of mild analgesics. Br J Clin Pharmacol 10: 395S–399S
The International Study of Agranulocytosis and Aplastic Anemia (1983) The design of a study of the drug etiology of agranulocytosis and aplastic anemia. Eur J Clin Pharmacol 24: 833–836
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levy, M., Flusser, D., Zylber-Katz, E. et al. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur J Clin Pharmacol 27, 453–458 (1984). https://doi.org/10.1007/BF00549594
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00549594